Literature DB >> 8498839

Elevated serum levels of tumor necrosis factor-alpha in Guillain-Barré syndrome.

M K Sharief1, B McLean, E J Thompson.   

Abstract

Activated T lymphocytes and macrophages play a putative role in the the pathogenesis of Guillain-Barré syndrome. Both cell types secrete tumor necrosis factor-alpha, a cytokine that has well-recognized toxic effects on myelin, Schwann cells, and endothelial cells. We determined serum and cerebrospinal fluid concentrations of tumor necrosis factor alpha in 26 patients with Guillain-Barré syndrome, 27 patients with other polyneuropathies, 30 patients with neurological diseases of the central nervous system, and 14 healthy control subjects. Markedly increased serum levels were detected in 14 patients (54%) with Guillain-Barré syndrome and to a significantly lesser extent, in patients with other polyneuropathies (26%) and in neurological control subjects (23%). Tumor necrosis factor-alpha was not detected in the cerebrospinal fluid of patients with Guillain-Barré syndrome or other polyneuropathies. Increased serum concentrations in patients with Guillain-Barré syndrome correlated directly with disease severity and these concentrations returned to normal in parallel with clinical recovery. These findings emphasize the complexity of the immune response in patients with Guillain-Barré syndrome and suggest that tumor necrosis factor-alpha may be important in the pathogenesis of peripheral demyelination in this disorder.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8498839     DOI: 10.1002/ana.410330606

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  15 in total

1.  Potential role of transforming growth factor-beta 1 in terminating the immune response in patients with Guillain-Barré syndrome.

Authors:  E Sindern; K Schweppe; L M Ossege; J P Malin
Journal:  J Neurol       Date:  1996-03       Impact factor: 4.849

Review 2.  Autoimmune responses in peripheral nerve.

Authors:  H P Hartung; H Willison; S Jung; M Pette; K V Toyka; G Giegerich
Journal:  Springer Semin Immunopathol       Date:  1996

3.  Linomide suppresses experimental autoimmune neuritis in Lewis rats by inhibiting myelin antigen-reactive T and B cell responses.

Authors:  J Zhu; X F Bai; G Hedlund; J Björk; M Bakhiet; P H Van Der Meide; H Link
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

4.  Distribution of endogenous tumour necrosis factor alpha in gliomas.

Authors:  M Maruno; J S Kovach; P J Kelly; T Yanagihara
Journal:  J Clin Pathol       Date:  1997-07       Impact factor: 3.411

Review 5.  Molecules involved in the crosstalk between immune- and peripheral nerve Schwann cells.

Authors:  Nevena Tzekova; André Heinen; Patrick Küry
Journal:  J Clin Immunol       Date:  2014-04-17       Impact factor: 8.317

6.  Circulating transforming growth factor beta 1 (TGF-beta1) in Guillain-Barré syndrome: decreased concentrations in the early course and increase with motor function.

Authors:  A Créange; L Bélec; B Clair; J D Degos; J C Raphaël; R K Gherardi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-02       Impact factor: 10.154

7.  Tumor necrosis factor alpha 308 G/A polymorphism and Guillain-Barré syndrome risk.

Authors:  Hong Jiao; Weizhi Wang; Huabing Wang; Yun Wu; Lihua Wang
Journal:  Mol Biol Rep       Date:  2011-05-22       Impact factor: 2.316

8.  Distribution patterns of demyelination correlate with clinical profiles in chronic inflammatory demyelinating polyneuropathy.

Authors:  S Kuwabara; K Ogawara; S Misawa; M Mori; T Hattori
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-01       Impact factor: 10.154

9.  Electrophysiological studies in Guillain-Barré syndrome: correlation with antibodies to GM1, GD1B and Campylobacter jejuni.

Authors:  F J Vriesendorp; W J Triggs; R F Mayer; C L Koski
Journal:  J Neurol       Date:  1995-07       Impact factor: 4.849

10.  Tumour necrosis factor-alpha and other cytokines in Guillain-Barré syndrome.

Authors:  A R Exley; N Smith; J B Winer
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-09       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.